osteoporosis
Conditions
Interventions
Teriparatide 20 microg is administrated subcutaneously once daily for 24 weeks.
Active vitamine D3 1.0 microg is orally administrated once daily for 24 weeks.
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Distal radial fracture with surgical treatment 2)Gender:any gender 3)Age:any ages but correspond with diagnostic criteria for primary osteoporosis 4)Cases who have ability to consent to the study 5)case expected to attend a hospital regularly as planned
Exclusion criteria
Exclusion criteria: 1)Primary malignant bone tumors or bone metastasis 2)Metabolic bone disease except primary osteoporosis 3)Under medication for osteoporosis(bisphosphonates, teriparatide, or SERM ) 4)Under medication of steroid 5)Hypercalcemia 6)Suspection of metal allergy 7)Dementia, Schizophrenia, Panic disorder and other diseases that may have affect the evaluation or obstruct obtaining consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is the comparison of the percent chage of bone mineral density (BMD)of the fracture site as measured by dual-energy x-ray absorptiometry(DEXA)with or without teriparatide administration from baseline to 24 weeks after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome is the comparison of the percent change in markers of bone formation and resorption with or without teriparatide administration from baseline to 24 weeks after surgery. | — |
Countries
Japan
Contacts
Public ContactHirohiko Ota
Yokohama City University Medical Center Orthopaedics
Outcome results
None listed